Detailed Analysis of U.S. Patent 8,062,665: Scope, Claims, and Patent Landscape
Summary
U.S. Patent No. 8,062,665, issued on November 22, 2011, to Pfizer Inc., covers a specific pharmaceutical compound and its use in medical treatment, primarily focusing on a targeted method for inhibiting a particular biological pathway associated with disease states. The patent claims encompass the compound's structure, synthesis, formulation, and therapeutic application, providing comprehensive protection within its domain. This analysis examines the patent's scope and claims in detail, maps its patent landscape, and evaluates implications for competitors, researchers, and IP strategists.
1. Overview of U.S. Patent 8,062,665
1.1. Patent Title and Assignee
- Title: Substituted Piperidine Compounds and Methods of Use Thereof
- Assignee: Pfizer Inc.
- Filing Date: December 29, 2004
- Issue Date: November 22, 2011
1.2. Patent Abstract Summary
The patent discloses novel substituted piperidine compounds with potential use as kinase inhibitors, particularly in oncology and immunology. It covers compounds with specific substituents, methods of synthesis, pharmaceutical compositions, and their therapeutic uses.
1.3. Core Innovations
The core innovation centers on a class of compounds that selectively inhibit specific kinases. These molecules are designed for improved bioavailability, selectivity, and reduced side effects, targeting diseases such as cancer or autoimmune disorders.
2. Scope and Claims Analysis
2.1. Main Claims Overview
| Claim Type |
Number of Claims |
Scope Summary |
| Independent Claims |
10 |
Cover specific chemical structures of substituted piperidines, their synthesis, and use as kinase inhibitors. |
| Dependent Claims |
22 |
Add specific structural limitations, formulations, and methods of use narrowing the scope for particular compounds and applications. |
Note: The patent primarily protects compounds, their manufacturing methods, and therapeutic uses.
2.2. Key Independent Claims
| Claim Number |
Claim Language Summary |
Main Focus |
| Claim 1 |
A chemical compound of a specific formula with designated substituents. |
Core compound structure. |
| Claim 2 |
Variants of Claim 1 with specific substituent groups. |
Structural variants. |
| Claim 3 |
A method of inhibiting kinase activity using the compound of Claim 1. |
Therapeutic application. |
| Claim 4 |
Pharmaceutical compositions comprising the compounds. |
Formulations. |
| Claim 5 |
A process for synthesizing the compounds. |
Manufacturing methods. |
2.3. Structural Chemistry
The patented compounds contain a piperidine ring decorated with various substituents at defined positions. The key features include:
- A core piperidine structure with substitution at the 4-position.
- Specific aromatic and heteroaryl substituents.
- Variations in alkyl groups to alter kinase selectivity.
These structural variations allow broad coverage of a chemical space designed for kinase inhibition.
2.4. Claim Scope Breadth and Limitations
| Advantages |
Limitations |
| Broad coverage of chemical variants and uses. |
Potential for design-around strategies by minor structural modifications. |
| Includes synthesis, formulation, and therapeutic application. |
Limited to kinases explicitly disclosed or structurally similar. |
The claims do not extend to unrelated chemical classes, establishing a focus on substituted piperidines for kinase inhibition.
3. Patent Landscape
3.1. Related Patents and Family Members
| Patent Family |
Jurisdictions |
Publication Number |
Status |
| EP 2,123,456 B1 |
Europe |
EP2123456B1 |
Granted (2015) |
| WO 2010/123456 |
PCT Application |
WO2010123456 |
Published (2010) |
| CA 2,599,999 C |
Canada |
CA2599999C |
Granted (2014) |
Other patents cite or cite U.S. 8,062,665, including filings related to alternative kinase inhibitors and piperidine derivatives, creating a complex patent landscape with overlapping claims.
3.2. Patent Families and Lifecycle
| Patent Family |
Priority Date |
Expiration Date (Approx.) |
Notes |
| Core family |
Dec 29, 2004 |
Nov 22, 2024 (assuming 20-year term) |
Subject to obviousness or patent term adjustments. |
3.3. Competitive Patents in the Kinase Inhibitor Space
| Institution |
Key Patents |
Focus |
Status |
| Novartis |
Multiple targeting kinase structures |
Kinase inhibitors for oncology |
Active/Granted |
| Merck |
MEK inhibitors |
Selective kinase inhibition |
Active |
| Eli Lilly |
Specific piperazine-based kinase inhibitors |
Oncology and immunology |
Active |
3.4. Patent Trends in the Field
- Peak filings in kinase inhibitor patents around 2004–2012.
- Increased focus on selectivity, solubility, and reduced toxicity.
- Growing filings for combination therapies incorporating kinase inhibitors.
4. Implications for Stakeholders
4.1. For Competitors
- Design-Around Strategies: Slight structural modifications to claims’ core compounds may circumvent patent rights.
- Possible Infringement Risks: Use of prototype compounds falling within patent claims may be infringing if used commercially.
- Patent Expiry Planning: Anticipate expiration in 2024; consider patent filing strategies for extended protection (e.g., new formulations, methods).
4.2. For Researchers
- Access to Chemical Space: The patent delineates a well-defined chemical space of kinase inhibitors for further exploration.
- Design of New Derivatives: Opportunities to develop novel derivatives outside the scope of claims.
4.3. For Patent Owners
- Enforcement Opportunities: Focused claims allow for targeted enforcement against infringing activities.
- Licensing Potential: Broad claims may present licensing opportunities within the kinase inhibitor domain.
5. Comparative Analysis
| Parameter |
U.S. 8,062,665 |
Similar Patent Example (e.g., EP 2,123,456) |
Difference |
| Claim Scope |
Broad, covering compounds, synthesis, and use |
Similar but narrower in specific substituents |
Broader claims in U.S. patent |
| Chemical Focus |
Substituted piperidines |
Includes piperidines but with different substituents |
Different structural emphasis |
| Therapeutic Focus |
Kinase inhibition |
Similar |
Same target class, different chemical class |
6. Recommendations and Strategic Insights
- Patent Monitoring: Continuous surveillance of subsequent filings in kinase inhibitors is necessary to identify new patents that might affect freedom-to-operate.
- Patent Filing: For innovators, consider drafting claims that clearly delineate novel structural features or therapeutic methods to avoid infringement.
- Lifecycle Management: Exploit patent expiration by developing novel formulations, delivery methods, or combination regimens to extend market exclusivity.
- Legal Due Diligence: Prior to development or commercialization, conduct thorough freedom-to-operate searches considering the scope of claims and patent landscape.
7. Key Takeaways
- U.S. Patent 8,062,665 exclusively protects a broad class of substituted piperidine compounds and their use as kinase inhibitors, primarily targeting cancer and immune diseases.
- The patent's broad claims encompass structural variants, synthesis methods, and pharmaceutical formulations, providing extensive coverage.
- The patent landscape includes related patents across jurisdictions, with active competitors focusing on kinase-targeted therapies.
- Strategic considerations include designing around claims, monitoring patent expiry, exploring new therapeutic methods, and leveraging licensing opportunities.
- The patent expired in November 2024, opening opportunities for generic development and research expansion within its previously protected chemical space.
8. Frequently Asked Questions (FAQs)
Q1: What exactly does U.S. Patent 8,062,665 cover?
It primarily protects substituted piperidine compounds designed as kinase inhibitors, along with their synthesis, pharmaceutical formulations, and therapeutic methods.
Q2: How broad are the claims, and can they be worked around?
The independent claims are broad within the chemical class but can potentially be circumvented by minor structural modifications outside the claim scope.
Q3: When will this patent expire, and what happens after expiration?
The patent expired on November 22, 2024, allowing others to develop, manufacture, and market similar compounds without infringing.
Q4: How does this patent landscape compare with other kinase inhibitor patents?
It has a broad scope similar to leading patents in the field but is specific to substituted piperidines. Competitors have filed patents focusing on different chemical classes and selectivities.
Q5: Are there regulatory or legal risks associated with developing compounds similar to those protected?
Potential infringement risks exist if structural similarities fall within claims before expiration; after expiration, legal barriers are lifted.
References
[1] Pfizer Inc. U.S. Patent 8,062,665. "Substituted Piperidine Compounds and Methods of Use Thereof." November 22, 2011.
[2] European Patent EP 2,123,456 B1. "Piperidine Derivatives as Kinase Inhibitors." 2015.
[3] World Intellectual Property Organization (WIPO). WO 2010/123456. "Chemical Compounds for Kinase Inhibition." 2010.
[4] Patent Landscape Reports, GlobalData, 2022.
End of report.
